Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

Johnson, PWM; Balasubramanian, S; Hodkinson, B; Shreeve, SM; Sun, SV; Srinivasan, S; Steele, AJ; Vermeulen, J; Sehn, LH; Wilson, WH

Johnson, PWM (通讯作者)，Univ Southampton, Southampton Gen Hosp, Ctr Canc Immunol, Southampton SO16 6YD, England.

BLOOD ADVANCES, 2023; 7 (10): 2008

Abstract

Diffuse large B-cell lymphoma (DLBCL), with high coexpression of BCL2 and MYC proteins (DE lymphoma), is considered an adverse prognostic indicator as......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索